Zydus gets USFDA nod for anti-hypertensive drug

Our Bureau Ahmedabad | Updated on November 25, 2017

Pharma major, Zydus Cadila today informed that the company has received the final approval from the US drug regulator to market Telmisartan tablets in the US market.

On Friday, the company stated that the US Food and Drug Administration (USFDA) has granted final approval to market Telmisartan Tablets of 20mg, 40mg and 80mg.

The estimated sales in 2014 for Telmisartan tablets, which fall in the anti-hypertensive segment is $233.3 million, as per IMS.

The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04, a company statement stated.

Published on August 29, 2014

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like